Q-omics provides the consensus-scored RPL22P8 profile across patient tissues and cancer cell-line models. RPL22P8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RPL22P8 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, RPL22P8 RNA expression shows 6,547 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight MESO, and BRCA as cancer lineages where RPL22P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL22P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL22P8 survival associations across molecular data types. RPL22P8 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL22P8 RNA expression–survival associations across cancer types. High RPL22P8 expression shows unfavorable associations in MESO and ACC, but favorable associations in BLCA, SKCM, THYM and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for RPL22P8 RNA expression.
This table summarizes RPL22P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL22P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL22P8 shows lower tumor expression in BRCA, CHOL and THCA and higher tumor expression in PRAD, LIHC and KIRC. The BRCA box plot shows higher RPL22P8 RNA expression in normal versus tumor tissue (log2 FC = −0.069, t-test p = .001).
This table shows molecular features associated with RPL22P8 in patient tissues and cancer cell lines. In patient samples, RPL22P8 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
